Welcome to our dedicated page for Bristol-Myers Squibb Co SEC filings (Ticker: BMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bristol-Myers Squibb Company SEC filings document the company’s pharmaceutical operating results, investor presentations, governance matters, registered securities and debt activity. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD presentations, annual-meeting vote results and other material events, including note offerings and tender-offer disclosures tied to the company’s capital structure.
The company’s proxy materials cover board elections, executive compensation, shareholder voting matters and corporate governance. Its registered securities disclosures include common stock, Celgene contingent value rights and multiple exchange-listed notes. Form 15 records also document the termination of registration for a $2 convertible preferred stock class with no holders of record, while other reporting obligations remain tied to listed securities.
Bristol Myers Squibb EVP and CFO David V. Elkins reported a series of equity compensation transactions involving company stock. He exercised derivative awards, converting 62,982 market share units and performance shares into common stock on March 10, 2026, as previously granted awards vested under performance-based plans. He also received new grants of 35,265 market share units and 52,898 performance share units that will vest in future years based on performance and Board certification. To cover tax obligations on these vestings, 16,114 shares of common stock were withheld at a price of $60.13 per share, which is a non-market tax payment rather than an open-market sale. Following these transactions, Elkins directly holds 189,248 shares of common stock and has an additional 291.17 shares held indirectly through the BMS Savings and Investment Program.
Bristol Myers Squibb executive Benjamin Hickey, President of the RayzeBio organization, reported equity compensation activity involving restricted stock units and common stock. On February 27, 2026, 3,286 restricted stock units were exercised or converted into 3,286 shares of common stock at $0.00 per share as they vested. In connection with this vesting, 1,672 common shares were withheld at $62.37 per share to cover tax obligations, a non‑open‑market disposition. After these transactions, Hickey directly held 16,672 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb is a global biopharmaceutical company focused on oncology, hematology, immunology, cardiovascular and neuroscience, generating $48,194 million in revenues for the year ended December 31, 2025, roughly flat versus 2024 and up from 2023.
The business is anchored by growth brands such as Opdivo, Eliquis, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati and Cobenfy, supported by broad patent and regulatory exclusivity across the U.S., EU and Japan. Legacy products including Revlimid, Pomalyst, Sprycel and Abraxane face generic erosion in key markets.
The company invested heavily in innovation, with $10.0 billion of R&D expense in 2025 and a pipeline of more than 45 assets across small molecules, biologics, ADCs, CAR-T and radiopharmaceuticals. New and expanded manufacturing facilities for cell therapies and radiopharmaceuticals were brought online in the U.S. and Europe.
Regulatory and pricing pressures are intensifying. Specific products, including Eliquis and Pomalyst, are subject to government-set Medicare prices under the Inflation Reduction Act, and Orencia has been selected for future “negotiation.” A 2025 agreement with the U.S. government adds further concessions, including providing Eliquis free to Medicaid and offering substantial direct-to-patient discounts on several brands.
Bristol-Myers Squibb Company furnished an update on its recent performance by issuing an earnings press release and investor presentation covering financial results for the fourth quarter of 2025 and the full year 2025.
The company posted the earnings press release and a “Bristol Myers Presentation” on its website in connection with an earnings conference call and webcast. Both materials include non-GAAP financial measures, with reconciliations and explanations provided in the press release. These materials are furnished, not filed, under the Exchange Act and are not automatically incorporated into future SEC filings.
Bristol Myers Squibb executive Gregory Scott Meyers reported equity compensation activity involving restricted stock units and common shares. On February 1, 2026, 2,543 restricted stock units vested and converted into 2,543 shares of common stock at an exercise price of $0, reflecting previously granted awards that vest annually in four equal installments beginning on February 1, 2023.
On the same date, 833 common shares were withheld at a price of $55.05 to cover taxes due upon vesting of the restricted stock units. After these transactions, Meyers directly owned 21,428 shares of Bristol Myers Squibb common stock.
Bristol Myers Squibb executive Benjamin Hickey reported routine equity compensation activity. On February 1, 2026, 10,079 restricted stock units vested, each converting into one share of common stock at an exercise price of $0.
To cover taxes on the vesting, 3,810 common shares were withheld at a price of $55.05 per share. After these transactions, Hickey directly owned 15,058 shares of Bristol Myers Squibb common stock and 10,079 restricted stock units remained outstanding, scheduled to vest in equal annual installments beginning February 1, 2025.
Bristol Myers Squibb director Phyllis R. Yale received 3,996.367 Deferred Share Units on February 1, 2026 at a reference price of $55.05 per unit. These derivative awards increase her holdings of Deferred Share Units to 43,326.695, all held directly.
Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when she ceases to be a director or at a future date she previously specified, and reflect deferred compensation and reinvested dividends under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Karen H. Vousden reported an award of derivative securities tied to company stock. On February 1, 2026, she acquired 3,996.367 Deferred Share Units at $55.05 each, bringing her total to 41,069.315 Deferred Share Units, held directly.
Each Deferred Share Unit converts into one share of Bristol Myers Squibb common stock upon settlement. These units become settleable when she ceases to be a director or at a future date she previously selected. The total includes deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Theodore R. Samuels II reported an automatic grant of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. After this award, he beneficially owns 67,882.504 Deferred Share Units in total.
Each Deferred Share Unit converts into one share of common stock when settled. These units become settleable when he ceases to be a director or on a future date he previously selected, and the total includes deferred compensation and reinvested dividends under the company’s deferred compensation plan for non-employee directors.
Bristol Myers Squibb director Derica W. Rice reported an award of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. This increased his holdings of Deferred Share Units to 39,324.809, which track common stock and are settled in shares later.
Each Deferred Share Unit converts into one share of common stock when he leaves the board or on a future date he previously selected. The holdings also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.